Lysophospholipids, exemplified by lysophosphatidic acid (LPA) and sphingosine 1-
phosphate (S1P), are produced by the metabolism and perturbation of biological …

Lysophosphatidic acid (LPA) is a small ubiquitous lipid found in vertebrate and
nonvertebrate organisms that mediates diverse biological actions and demonstrates …

Chronic pain is a major challenge to clinical practice and basic science. The peripheral and
central neural networks that mediate nociception show extensive plasticity in pathological …

Lysophosphatidic acid (LPA) is a small, ubiquitous phospholipid that acts as an extracellular
signaling molecule by binding to and activating at least five known G protein–coupled …

Lysophospholipids encompass a diverse range of small, membrane‐derived phospholipids
that act as extracellular signals. The signalling properties are mediated by 7 …

Abstract Treatment of neuropathic pain, triggered by multiple insults to the nervous system,
is a clinical challenge because the underlying mechanisms of neuropathic pain …

Fingolimod is the first oral disease-modifying therapy approved for relapsing forms of
multiple sclerosis (MS). Following phosphorylation in vivo, the active agent, fingolimod …

The brain is composed of many lipids with varied forms that serve not only as structural
components but also as essential signaling molecules. Lysophosphatidic acid (LPA) is an …

For decades lysophosphatidylcholine (LPC, lysolecithin) has been used to induce
demyelination, without a clear understanding of its mechanisms. LPC is an endogenous …

BACKGROUND & AIMS: Pruritus is a common and disabling symptom in cholestatic
disorders. However, its causes remain unknown. We hypothesized that potential pruritogens …